

## Allegato E

# MARTA VALENZA

## Curriculum Vitae ai fini della pubblicazione

Rome, May 20<sup>th</sup>, 2023

### Part I – General Information

Full Name	MARTA VALENZA
Date of Birth	
Place of Birth	
Citizenship	
Permanent Address	
Mobile Phone Number	
E-mail	
Pec e-mail	
Spoken Languages	ITALIAN: native ENGLISH fluent (speaking, reading, writing)
National Scientific Qualification	<b>National Scientific Qualification to Associate Professor in Pharmacology.</b> (Abilitazione Scientifica Nazionale a Professore di II fascia; SC: 05/G1 – SSD: BIO/14) from the Italian Ministry of Education, University and Research (MIUR) obtained in May 2021 and valid through 2030
Current position	Research contract (collaborazione autonoma) with the pharmaceutical company Epitech Group SpA Saccolongo (PD), Italy
Leave of absence	Maternity leave Maternity leave

### Part II – Education

Type	Year	Institution	Notes (Degree, Experience, ...)
PhD	15/04/2013	University of Bari “Aldo Moro”. Bari, Italy	<b>PhD in Clinical Pharmacology and Medical Therapy.</b> Final evaluation: excellent. Thesis title: “ <i>Brain reward function and depressive-like behavior in rodent models of eating disorders and obesity</i> ”. Mentors: Prof. Maria Rosaria Carratù, MD and Professor of Pharmacology at University of Bari and Prof. Pietro Cottone, PhD Boston University School of Medicine, Boston (MA) US

Master's Degree	22/07/2009	SAPIENZA University of Rome. Rome, Italy	<b>Pharmacy Degree in Medicinal Chemistry</b> (Laurea specialistica in Chimica e Tecnologia Farmaceutiche). Experimental thesis in Pharmacology (BIO/14 – 05/G1) title: “ <i>Cannabidiol's anti-inflammatory and neuroprotective effects in an in vitro model of Alzheimer's disease</i> ”. Mentor: Prof. Luca Steardo, MD, Sapienza University of Rome
Professional License	11/2009	SAPIENZA University of Rome, Rome, Italy	<b>Board-Certified Pharmacist</b>
Language knowledge Certificate	03/2001	British Council of Rome	First Certificate in English (FCE) University of Cambridge. Grade B2
Language knowledge Certificate	12/2000	Trinity College of Rome	Exam in Spoken English for non-English speakers. Grade 8 - B2.2

## Part II-B – Scientific and technical qualifications

Type	Year	Institution	Notes (Degree, Experience, ...)
Professional Certificate	28/04/2023	SAPIENZA Università di Roma Centro Ricerca e Servizi Sperimentazione preclinica e benessere animale	<b>Courses</b> with final exam (passed) covering modules <b>to work with animal models (D.L.08/21)</b> : Module 3.2 (practice) Biologia appropriata di base (rattus norvegicus) Module 8 (practice) Procedure minimamente invasive senza anestesia (rattus norvegicus)
Professional Certificate	11/2022	Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna	<b>Courses</b> with final exam (passed) covering modules <b>to work with animal models (D.L.08/21)</b> : Modules 1 e 2: “Legislazione nazionale ed etica livello 1”. Modules 3.1, 4, 5, 6.1, 7. “Biologia e gestione degli animali da laboratorio. Roditori e lagomorfi” Modules 9, 10 e 11. “Etica e concezione dei progetti”
Postdoctoral education	05/2016	The American Association for the Advancement of Science (AAAS/Science) Translational Medicine. The New York Academy of Sciences - New York, NY	Course (2 full days) “The 6th Aspen Brain Forum: The Addicted Brain and New Treatment Frontiers.”
Postdoctoral education	2016	The Rockefeller University - New York, NY, US	Course (8 hours) in “Ethics in Scientific Research”.

Professional Certificate	2016	The New York Academy of Sciences - New York, NY, US	The Science PhD Certificate: a leadership preparation course (40 hours) for scientists in Business, Academia, Government and Scientific Institutes
Postdoctoral education	2015	The Rockefeller University New York, NY, US	Science Communication and Writing Course (15 hours)
Postdoctoral education	06/2013	The Rockefeller University New York, NY, US	Laboratory Safety Training Radioactivity and radioisotopes - laboratory safety training module Training on animal care and use Training on aseptic surgery in rodents
Professional Certificate	2012	Boston University School of Medicine di Boston (MA)	Advanced Responsible Conduct of Research Program (Corso avanzato in conduzione responsabile della ricerca scientifica, titolo necessario per scienziati che lavorano su progetti finanziati dal National Institute of Health statunitense). 40-hour course with final examination.
Postgraduate education	2011 -2012	Boston University School of Medicine - Boston, MA, US	Boston University Transformative Training - Program in Addiction Science (series of seminars on addiction)
Postgraduate education	07/2011	Boston University School of Medicine - Boston, MA, US	Laboratory Safety Training Institutional Animal Care and Use Committee training Aseptic surgery training
International PhD program Summer School	2010	Université Lille Nord de France - Lille, FR	Summer School of Neuroscience in “Early Programming of Adult Modern Diseases” (1 full week)

### Part III – Appointments

#### III-A – Academic Appointments at international universities

01/09/2016	31/12/2017	THE ROCKEFELLER UNIVERSITY Laboratory of the Biology of Addictive Diseases, New York (NY) US. Head: Prof. Mary Jeanne Kreek, MD	<b>Postdoctoral Associate</b>
01/05/2013	31/08/2016	THE ROCKEFELLER UNIVERSITY Laboratory of the Biology of Addictive Diseases, New York (NY) US. Head: Prof. Mary Jeanne Kreek, MD	<b>Postdoctoral Fellow</b>

1/07/2011	30/04/2013	BOSTON UNIVERSITY School of Medicine, Boston (MA) US. Department of Pharmacology and Experimental Therapeutics. Lab. Prof.Cottone P and Sabino V., PhD	Research fellow
-----------	------------	--	-----------------

### III-B – Academic Appointments at national universities

Start	End	Institution	Position
01/2023	present	Faculty of Pharmacy and Medicine SAPIENZA University of Rome	<b>Expert in the field of “Farmacologia generale e molecolare”</b> (Cultore della materia in “Farmacologia generale e molecolare”) SSD: BIO/14.
09/2021	present	Faculty of Pharmacy and Medicine SAPIENZA University of Rome	<b>Expert in the field of “Toxicology”</b> (Cultore della materia in “Tossicologia”) SSD: BIO/14.
09/2021	present	Faculty of Pharmacy and Medicine SAPIENZA University of Rome	<b>Expert in the field of “Experimental pharmacology”</b> SSD: BIO/14. (Cultore della materia in “Farmacologia sperimentale”).
09/2021	09/2022	Faculty of Pharmacy and Medicine SAPIENZA University of Rome	<b>Expert in the field of “Applied pharmacology and phytovigilance”</b> SSD: BIO/14. (Cultore della materia in “Farmacologia applicata e fitovigilanza”).
05/2022	present	<b>PhD program in Pharmacology and Toxicology</b> (Corso di dottorato in Farmacologia e Tossicologia). Dept. of Physiology and Pharmacology SAPIENZA University of Rome	<b>Lecturer</b> in Principles of Pharmacoepidemiology (Docente dell’insegnamento di Principi di base della Farmacoepidemiologia)
09/2021	present	<b>Residency Program in Hospital Pharmacy</b> (Scuola di Specializzazione in Farmacia Ospedaliera). Dept. of Chemistry and Technologies of Drugs SAPIENZA University of Rome	<b>Member of the Residency Program Committee</b> (membro del Consiglio della Scuola di Specializzazione in Farmacia Ospedaliera) <b>Lecturer</b> in Pharmacovigilance (Docente dell’insegnamento di Farmacovigilanza)
01/05/2021	30/04/2022	Dept. of Physiology and Pharmacology “V. Erspamer” SAPIENZA University of Rome	<b>Postdoctoral Fellow</b> (Assegno di ricerca tipo II - cat. B; SC: 05/G1 – SSD: BIO/14).
01/01/2010	31/12/2012	University of Bari “Aldo Moro”	<b>PhD student</b> enrolled in the PhD program in Clinical Pharmacology and Medical Therapy (XXV cycle). Coordinator: Prof. Maria Rosaria Carratù, MD

23/07/2009	31/12/2009	Department of Physiology and Pharmacology "V. Erspamer". SAPIENZA University of Rome	<b>Postgraduate research activity</b> Research activities in the field of Pharmacology (05/G1– BIO/14) in the laboratory of Prof. Luca Steardo, MD,
01/10/2007	22/07/2009	Department of Physiology and Pharmacology "V. Erspamer". SAPIENZA University of Rome	<b>Undergraduate research internship</b> Research activities carried out to prepare the experimental thesis in Pharmacology (05/G1– BIO/14) in the laboratory of Prof. Luca Steardo, MD

### III-C – Other Appointments

Start	End	Institution	Position
01/09/2022	present (end date 31.12.2023)	Epitech Group SpA pharmaceutical company. Saccolongo (PD), Italy	<b>Research contract</b> (collaborazione autonoma). Project title: "Studio degli effetti di palmitoiletanolamide (PEA)/Luteolina colultramiconizzata e PEA-oxazolina coultramiconizzata sulla modulazione della funzionalità gliale, la neuroinfiammazione e i processi neurodegenerativi in modelli preclinici di malattia di Alzheimer."
01/01/2019	31.12.2020	Epitech Group SpA pharmaceutical company. Saccolongo (PD), Italy	<b>Research contract</b> (collaborazione autonoma). Project title: "Studio degli effetti di palmitoiletanolamide (PEA)/Luteolina colultramiconizzata e PEA-oxazolina coultramiconizzata sulla modulazione della funzionalità gliale, la neuroinfiammazione e i processi neurodegenerativi in modelli preclinici di malattia di Alzheimer."

### Part IV – Teaching experience

#### IV-A – Academic courses as appointed professor (titolare del corso/modulo) in the biomedical field

Year	Institution	Course	Sector
02/2023 – present	<b>II level Master Course</b> "Ricerca, Sviluppo e Management dell'Azienda Nutraceutica e Cosmetica". Faculty of Pharmacy and Medicine. SAPIENZA University of Rome	Approccio EVIDENCE-BASED alla progettazione e alla sperimentazione di nutraceutici e cosmeceutici e cenni di statistica applicata alle discipline biomediche - 0.5 CFU (4 hours)  Teaching duty assigned following a <b>public selection</b>	BIO/14
09/2021 – present	<b>PhD program</b> in Toxicology and Pharmacology (Corso di dottorato in Farmacologia e Tossicologia). Faculty of Pharmacy and Medicine SAPIENZA University of Rome	Principles of Pharmacoepidemiology (Principi di base della Farmacoepidemiologia). 1 CFU (8 hours)	BIO/14

09/2021 – present	<b>Residency School in Hospital Pharmacy</b> (Scuola di specializzazione in Farmacia Ospedaliera). Faculty of Pharmacy and Medicine. SAPIENZA University of Rome	Farmacovigilanza - 1 CFU (8 hours)	BIO/14
02/2022 – 01/2023	<b>II level Master Course</b> “Ricerca, Sviluppo e Management dell’Azienda Nutraceutica e Cosmetica”. Faculty of Pharmacy and Medicine SAPIENZA University of Rome	Approccio EVIDENCE-BASED alla progettazione e alla sperimentazione di nutraceutici e cosmeceutici e cenni di statistica applicata alle discipline biomediche - 0.5 CFU (4 hours) Teaching duty assigned following a <b>public selection</b>	BIO/14
2021-2022	Workshop/educational course “La filiera della Cannabis Sativa L: aspetti agronomici, chimico-analitici, medico-tossicologici, economico-legislativi”. Dept. of Chemistry and Drug Technologies. SAPIENZA University of Rome	Proprietà farmaco-tossicologiche della cannabis: dall’abuso alla terapia” - 0.25 CFU (2 hours) Teaching duty assigned following a <b>public selection</b>	BIO/14
02/2021 – 01/2022	<b>II level Master Course</b> “I manager chiave nell’azienda cosmeceutica e nutraceutica”. Faculty of Pharmacy and Medicine SAPIENZA University of Rome	Approccio EVIDENCE-BASED alla progettazione e alla sperimentazione di nutraceutici e cosmeceutici e cenni di statistica applicata alle discipline biomediche - 0.5 CFU (4 hours) Teaching duty assigned following a <b>public selection</b>	BIO/14
02/2020 – 01/2021	<b>II level Master Course</b> “I manager chiave nell’azienda cosmeceutica e nutraceutica”. Faculty of Pharmacy and Medicine SAPIENZA University of Rome	Statistica applicate alle discipline biomediche - 0.5 CFU (4 hours) Teaching duty assigned following a <b>public selection</b>	BIO/14

#### IV-B – Other teaching activities in the biomedical field

Year	Institution	Activity
2019 – present	Faculty of Pharmacy and Medicine. SAPIENZA University of Rome	<b>Co-mentor</b> of 8 experimental thesis for the Master’s Degree in Pharmacy, the Master’s Degree in Medicinal Chemistry (CTF) and the Bachelor’s Degree in Applied Pharmaceutical Sciences (SFA).
2019 – 2021	Scuola Leonardo da Vinci, Rome Italy	<b>Biology Course (30 hours) held in English</b> to international undergraduate students as preparation course for the International Medical Admission Test.

2018 – 2021	Scuola Leonardo da Vinci, Rome Italy	<b>Chemistry Course (23 hours) held in English</b> to international undergraduate students as preparation course for the International Medical Admission Test.
2015 – 2016	THE ROCKEFELLER UNIVERSITY New York (NY) US	<b>Mentor</b> within the Summer Undergraduate Research Fellowship at The Rockefeller University. Final student's poster presentation: Sherman JD, Kreek MJ, Valenza M. <i>Characterization of 18-hour self-administration of cocaine in rats</i>
2011 – 2013	Dept. of Pharmacology and Exp. Therapeutics. BOSTON UNIVERSITY School of Medicine, Boston (MA)	<b>Lab supervisor</b> for 5 pre-medical undergraduate students, three of which subsequently won a fellowship or an award.
2009 – 2011	Dept. Physiology and Pharmacology SAPIENZA University of Rome,	<b>Lab supervisor</b> for 4 undergraduate students

#### IV-C – Seminars in academic courses (attività didattica integrativa) in the biomedical field

Year	Institution	Course
2019 – present	Faculty of Pharmacy and Medicine SAPIENZA University of Rome	Seminar (6 hours) on “Statistics applied to biomedical sciences” held within the course of Toxicology of the Master’s Degree in Pharmacy.
2019 – present	Faculty of Pharmacy and Medicine SAPIENZA University of Rome	Seminar (4 hours) on “Statistica applicata alle discipline biomediche” held within the course of Experimental Pharmacology of the Bachelor’s Degree in Applied Pharmaceutical Sciences (SFA).

#### IV-D – Academic exam committee member

Year	Institution	Exam	Sector
01/2023 - present	Master’s Degree in Pharmacy, Faculty of Pharmacy and Medicine SAPIENZA University of Rome	General and molecular pharmacology	BIO/14
2021 – present	Master’s Degree in Pharmacy, Faculty of Pharmacy and Medicine. SAPIENZA University of Rome	Toxicology	BIO/14
2021 – present	Bachelor’s Degree in Applied Pharmaceutical Sciences (SFA), Faculty of Pharmacy and Medicine. SAPIENZA University of Rome.	Experimental pharmacology	BIO/14
2021 – 2022	Bachelor’s Degree in Applied Pharmaceutical Sciences (SFA), Faculty of Pharmacy and Medicine. SAPIENZA University of Rome.	Applied pharmacology and phytovigilance	BIO/14

## Part V – Awards and Honors

Year	Title
08.04.2020	<b>Paper selected for a NIDA note</b> ( <a href="https://www.drugabuse.gov/news-events/nida-notes">https://www.drugabuse.gov/news-events/nida-notes</a> ) entitled “Targeting the kappa receptor to reduce drug use and relapse” published as first and corresponding author in Psychopharmacology (doi: 10.1007/s00213-019-05444-4) by the National Institute of Drugs of Abuse (NIDA-NIH).
01.07.2015	<b>Career Development Travel Award</b> from the Postdoctoral Association (PDA) of the Rockefeller University, New York (NY) (500 \$), awarded following a competitive announcement
26.09.2013	<b>Excellence in Science Program Award</b> from The American Association for the Advancement of Science AAAS/Science for postdoc with merit, awarded following a competitive announcement.
03.08.2012	<b>Recognition of high scientific quality for the paper</b> entitled "Antagonism of sigma-1 receptors blocks compulsive-like eating", published as co-author in Neuropsychopharmacology (doi: 10.1038/npp.2012.89), that was selected as a "hot paper" by the National Institute of Drugs of Abuse (NIDA-NIH).

## Part VI – Scientific Memberships

### Part VI-A – Scientific Boards

06/2015 - 09/2017	Academic member of the Application Review Committee for the Summer Science Research Program at the Rockefeller University, New York (NY) (membro di commissione per la selezione dei candidati al programma estivo di ricerca della Rockefeller University)
----------------------	---

### Part VI-B – Scientific Societies

2010 - 2013	Member of the Italian Society of Pharmacology (Società Italiana di Farmacologia, SIF)
2019 - present	
2022 - present	Member of the Brainstorming Research Assembly for Young Neuroscientists (BraYn)
2022 - present	Member of the Mediterranean Neuroscience Society (MNS)
2012 - 2019	Member of the Society for Neuroscience (SfN)
2014 - 2018	Member of the New York Academy of Sciences (NYAS)
2013 - 2017	Member of the Rockefeller University Association “Women in Science at Rockefeller”
2013 - 2016	Member of The American Association for the Advancement of Science (AAAS/Science)



## Part VII – Funding Information

### Part VII-A – Fellowships

Year	Title
01/05/2021	<b>Postdoctoral fellowship</b> from the Dept of Physiology and Pharmacology “V. Erspamer” at Sapienza University of Rome (Assegno di ricerca tipo II - cat. B; SC: 05/G1 – SSD: BIO/14). Research project titled “Studio degli effetti dei modulatori dei recettori attivati dai proliferatori dei perossisomi nella maturazione degli oligodendrociti in condizioni di invecchiamento fisiologico e patologico”. <b>Role: Principal Investigator</b>
01.05.2016	<b>The Kopf Family Foundation Fellowship</b> – 1-year postdoctoral fellowship to support my research studies in the laboratory of the Biology of Addictive Diseases at the Rockefeller University, New York (NY) on the effects of a novel kappa opioid receptor antagonist in animal models of cocaine addiction. <b>Role: Principal Investigator</b>
01.05.2015	<b>The Dorothea Dix Fellowship Award</b> – 1-year postdoctoral fellowship to support my research project in the laboratory of the Biology of Addictive Diseases at the Rockefeller University, New York (NY) investigating the role of the kappa opioid receptor in cocaine addiction. <b>Role: Principal Investigator</b>
01.05.2014	<b>The Dorothea Dix Fellowship Award</b> – 1-year postdoctoral fellowship to support my research projects in the laboratory of the Biology of Addictive Diseases at the Rockefeller University, New York (NY) on new therapeutic approaches for the treatment of neuropsychiatric diseases. <b>Role: Principal Investigator</b>
01.05.2013	<b>The Dorothea Dix Fellowship Award</b> – 1-year postdoctoral fellowship to support my research projects in the laboratory of the Biology of Addictive Diseases at the Rockefeller University, New York (NY) on the neurobiology of neuropsychiatric diseases. <b>Role: Principal Investigator</b>
01.07.2011 – 30.04.2013	<b>Fellowship</b> from the Boston University School of Medicine (Boston, MA) (27804\$).
06/2011	Approval for a <b>50% rise of the fellowship</b> to conduct research abroad for 18 months-PhD program in Clinical Pharmacology and Medical Therapy at University of Bari “Aldo Moro”, Bari, Italy
01.01.2010 – 31.12.2012	<b>Individual three-year fellowship</b> - PhD program in Clinical Pharmacology and Medical Therapy at University of Bari “Aldo Moro”, Bari, Italy

## Part VII -B – Grants as Investigator or Principal Investigator

Year	Title	Program	Grant value
16.11.2021	Studio sul possibile ruolo delle cellule gliali nel binge-eating disorder	Starting grant (Progetti per Avvio alla Ricerca – tipo II). Numero protocollo: AR22117A5DC9F3F2. SAPIENZA University of Rome <b>Role: Principal Investigator</b>	
2019	Studio degli effetti di palmitoiletanolamide (PEA)/Luteolina co-ultramicronizzata e PEA-Oxazolina co-ultramicronizzata sulla modulazione della funzionalità gliale, la neuroinfiammazione e i processi neurodegenerativi in modelli preclinici di malattia di Alzheimer	Epitech Group Spa – Research Contract. PI: Prof. Caterina Scuderi, SAPIENZA University of Rome. <b>Role: Investigator</b>	
01.04.2013 – 30.03.2018	The translation research on addiction treatment and the mechanisms of drug addiction	Dr. Miriam and Sheldon G. Adelson Medical Research Foundation. PI: Prof. Mary Jeanne Kreek, The Rockefeller University, New York (NY). <b>Role: Investigator</b>	
2013	Treatments for addictions – biological correlates	National Institute of Drug of Abuse (NIDA). Project N. 5P60DA005130-25. PI: Prof. Mary Jeanne Kreek, The Rockefeller University, New York (NY). <b>Role: Investigator</b>	
01.06.2011 - 31.05.2013	Role of sigma receptors in ethanol reinforcement	National Institute of Alcohol abuse and alcoholism (NIAAA) Project N. 5R00AA016731-05. PI: Prof. Valentina Sabino, Boston University (MA) <b>Role: Investigator</b>	
2011 - 2015	Role of the endocannabinoid system in compulsive eating	National Institute of Mental Health (NIMH). Project N. 5R01MH091945. PI: Prof. Pietro Cottone, Boston University (MA). <b>Role: Investigator</b>	

## Part VIII – Research Activities

Keywords	Brief Description
Neuropsychopharmacology Molecular pharmacology Behavioral Pharmacology	My research activities fall into the field of neuropsychopharmacology, using both behavioral and molecular approaches, with the translational aim to develop novel therapeutic approaches for specific neuropsychiatric disorders.
Neuroglia Alzheimer’s disease Neuroinflammation Palmitoylethanolamide Stress-related disorders	<p>My primary research interest focuses on <b>understanding the role of glial cells in neuropsychiatric diseases</b>.</p> <p>I have been studying the responses of glial cells to <math>\beta</math>-amyloid and the glial molecular mechanisms underlying neuroinflammation using several <i>in vitro</i> and <i>in vivo</i> experimental models of Alzheimer’s disease. <u>Achievements:</u> I contributed to demonstrate that formulations containing cannabidiol or palmitoylethanolamide dampen <math>\beta</math>-amyloid-induced neuroinflammation and modulate reactivity of both microglia and astrocytes through the interaction with different isoforms of the peroxisome proliferator-activated receptors, ultimately protecting neurons from damage. Also, chronic administration of formulations containing palmitoylethanolamide ameliorates behavioral parameters of memory and cognition and changes brain content of specific metabolites in animal models of Alzheimer’s disease.</p> <p>I am also investigating the possible alteration of glial cells functions in psychiatric disorders with behavioral manifestations. I am currently collaborating to projects studying both morphological and functional alterations of glial cells in animal models of binge-eating disorders and acute traumatic stress. <u>Achievements:</u> I am about to publish the selective presence of glial reactivity and neuronal alterations in the prefrontal cortex of rats vulnerable to a single acute stress exposure, but not in resilient rats, with an intriguing therapeutic effect of ketamine in preventing some alterations.</p>
Psychiatric diseases Addiction Eating Disorders	My second line of research aims at elucidating the <b>neurobiological basis of addiction to discover novel pharmacological targets to develop new therapeutics</b> . In this regard, I had extensive training in prestigious international laboratories. <u>Achievements:</u> I developed and characterized a new protocol of extended-access (18h) self-administration to cocaine in rats, able to mimic experiences of cocaine dependence in humans. Using this protocol, I provided the first <i>in vivo</i> evidence of the benefit of short-acting kappa opioid receptor antagonists for treating some behavioral aspects of cocaine dependence. I have also demonstrated <i>in vivo</i> that some genetic factors predispose subjects to become addicted to specific drugs of abuse, as ethanol and cocaine, or to natural rewards, like energy-dense food leading to obesity. I studied the role of abnormal responsivity to stress in initiation, perpetuation, and relapse to food, ethanol, and cocaine addiction. I have tested several drugs with potential translational relevance to counteract specific altered behaviors related to psychiatric diseases such as kappa opioid receptor antagonists, memantine, rimonabant and modulators of sigma receptors and oxytocin receptors.

## Part IX – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Published Papers and editorial [international, peer-reviewed]	27	Scopus	2011	2023
Published Conference meeting abstracts [international, published in peer-reviewed journals]	6	Clarivate JCR-Web of Science	2011	2021
<b>Total Impact factor</b> of the 27 peer-reviewed publications				
Total Impact factor of the 6 published abstracts				
<b>Average Impact factor</b> per peer-reviewed publication (abstracts excluded)				
Average Impact factor per abstract				
<b>Total Citations</b> of published peer-reviewed publications				
<b>Average Citations</b> per published peer-reviewed publication (abstracts excluded)				
<b>Hirsch (H) index</b>				
<b>H index of last 10 years (2013-2023)</b>				
<b>H index of last 8 years (2015-2023)</b>				

## Part X – Selected Publications

*Type of publication from Scopus. Impact Factor of the year of publication from Clarivate-Journal Citation Report; Citations from Scopus or Web of Science.*

1. **Valenza M**, Facchinetti R, Steardo L, Scuderi C. *Palmitoylethanolamide and White Matter Lesions: Evidence for Therapeutic Implications*. BIOMOLECULES 2022; 12(9):1191. Review. IF(2021)=6.064; citations=0
2. Facchinetti R <sup>1</sup>, **Valenza M** <sup>1</sup>, Chiara Gomiero, Giulia Federica Mancini, Luca Steardo, Patrizia Campolongo, Scuderi C. *Co-Ultramicronized Palmitoylethanolamide/Luteolin Restores Oligodendrocyte Homeostasis via Peroxisome Proliferator-Activated Receptor- $\alpha$  in an In Vitro Model of Alzheimer's Disease*. BIOMEDICINES 2022 May 26;10(6):1236. Article. IF(2021)=4.757; citations=4. **<sup>1</sup>co-first authors**.
3. **Valenza M**, Scuderi C. *How useful are biomarkers for the diagnosis of Alzheimer's disease and especially for its therapy?* NEURAL REGENERATION RESEARCH 2022 Oct;17(10):2205-2207. Article. IF(2021)=6.058, citations=5
4. **Valenza M**, Facchinetti R, Menegoni G, Steardo L, Scuderi C. *Alternative targets to fight Alzheimer's disease: Focus on astrocytes*. BIOMOLECULES 2021. Apr 19;11(4):600. Review. IF(2021)=6.064; citations=14
5. **Valenza M**, Steardo L Jr, Steardo L, Verkhratsky A and Scuderi C. *Systemic Inflammation and Astrocyte Reactivity in the Neuropsychiatric Sequelae of COVID-19: Focus on Autism Spectrum Disorders*. FRONTIERS in CELLULAR NEUROSCIENCE 2021. 15, 748136. Article. IF(2021)=6.147; citations=6
6. Facchinetti R <sup>1</sup>, **Valenza M** <sup>1</sup>, Bronzuoli MR, Ratano P, Steardo L, Campolongo P and Scuderi C. *Looking for a treatment for the early stage of Alzheimer's disease: Preclinical evidence with co-ultramicrosized palmitoylethanolamide and luteolin*. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 2020. May 27;21(11):E3802. Article. IF(2020)=5.924; citations=15. **<sup>1</sup>co-first authors**.
7. **Valenza M**, Blasio A, DiLeo A, Cottone P, Sabino V. *Sigma receptor-induced heavy drinking in rats: Modulation by the opioid receptor system*. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR 2020. May;192:172914. Article. IF(2020)=3.533; citations=4.
8. **Valenza M \***, Windisch KA, Butelman RE, Reed B, Kreek MJ *Effects of Kappa opioid receptor blockade by LY2540240, a selective short-acting antagonist, during chronic extended-access cocaine self-administration and re-exposure in rat*. PSYCHOPHARMACOLOGY 2020. Apr;237(4):1147-1160. Article. IF(2020)=4.530; citations=10. **\*corresponding author**.
9. **Valenza M \***, Facchinetti R, Steardo L and Scuderi C. *Altered waste disposal system in aging and Alzheimer's disease: focus on astrocytic aquaporin-4*. FRONTIERS in PHARMACOLOGY 2020. Jan 29;10:1656. Collection 2019. Article. IF(2020)=5.811; citations=42. **\*corresponding author**.
10. **Valenza M \***, Butelman R E, Kreek MJ. *Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats*. PSYCHOPHARMACOLOGY 2017. 234: 2219. Article. IF(2017)=3.222; citations=36. **\*corresponding author**.

11. **Valenza M \***, Picetti R, Yuferov V, Butelman R E, Kreek MJ. *Strain and cocaine-induced differential opioid gene expression may predispose Lewis but not Fischer rats to escalate cocaine self-administration*. NEUROPHARMACOLOGY 2016. Jun;105:639-50. Article. IF(2016)=5.012; citations=22. **\*corresponding author**.
12. **Valenza M**, Steardo L, Sabino V, Cottone P. *Diet-Induced Obesity and Diet-Resistant rats: differences in the rewarding and anorectic effects of D-Amphetamine*. PSYCHOPHARMACOLOGY (Berl). 2015 Sep;232(17):3215-26. Article. IF(2015)=3.540; citations=24.

<b>Total Impact factor</b> of the 12 selected peer-reviewed publications (referred to the year of publication)	<b>60.7</b>
<b>Average Impact factor</b> per peer-reviewed publication	<b>5.1</b>
<b>Total Citations</b> of the 12 selected peer-reviewed publications	<b>215</b> (with correction for maternity leave)
	184 (without correction)
<b>Average Citations</b> per peer-reviewed publication	<b>18</b> (with correction for maternity leave)
	15 (without correction)

Position of **first** and/or **corresponding author** in 12 out of 12 (**100 %**) peer-reviewed publications, of which 5 with  $IF \geq 6$  (**42 %**),  
and 7 with  $IF \geq 5$  (**58 %**).

#### **Part XI – International and national collaborators**

- Prof. Alexei Verkhratski, University of Manchester, UK
- Prof. Mary Jeanne Kreek, The Rockefeller University, New York (NY) USA (deceased in 2021)
- Prof. Eduardo R. Butelman, Mount Sinai School of Medicine, New York (NY) USA
- Prof. Carla Nasca, New York University, New York (NY) USA
- Prof. Wendy Walwyn, University of California Los Angeles, Los Angeles (CA) USA
- Prof. Caterina Scuderi, Sapienza University of Rome, Italy
- Prof. Patrizia Campolongo, Sapienza University of Rome, Italy
- Dr. Kyle W. Windisch, The Rockefeller University, New York (NY) US
- Prof. Pietro Cottone, Boston University School of Medicine, Boston (MA) USA
- Prof. Valentina Sabino, Boston University School of Medicine, Boston (MA) USA

## Part XII – Scientific Achievements

### XII-A – List of publications in extenso in peer-reviewed journals

*Type of publication from Scopus. Impact Factor of the year of publication from Clarivate-Journal Citation Report; Citations from Scopus or Web of Science. Added information about personal contribution when I am not a preeminent author of the publication (first/last/corresponding)*

[The 12 publications selected for the evaluation are the number 2, 3, 4, 5, 7, 8, 9, 10, 11, 13, 14, and 17 as reported in the Part IX– Selected Publications].

1. Bonifacino T, Mingardi J, Facchinetti R, Sala N, Frumento G, Ndoj E, **Valenza M**, Paoli C, Ieraci A, Torazza C, Balbi M, Guerinoni M, Muhammad N, Russo I, Milanese M, Scuderi C, Barbon A, Steardo L, Bonanno G, Popoli M, Musazzi L. *Changes at glutamate tripartite synapses in the prefrontal cortex of a new animal model of resilience/vulnerability to acute stress*. TRANSLATIONAL PSYCHIATRY 2023. Feb 18;13(1):62. Article. IF(2021)=7.989; citations=0. **Contribution:** statistical analysis, data interpretation, and writing responses to reviewers.
2. **Valenza M**, Facchinetti R, Steardo L, Scuderi C. *Palmitoylethanolamide and White Matter Lesions: Evidence for Therapeutic Implications*. BIOMOLECULES 2022; 12(9):1191. Review. IF(2021)=6.064; citations=0
3. Facchinetti R <sup>1</sup>, **Valenza M** <sup>1</sup>, Chiara Gomiero, Giulia Federica Mancini, Luca Steardo, Patrizia Campolongo, Scuderi C. *Co-Ultramicronized Palmitoylethanolamide/Luteolin Restores Oligodendrocyte Homeostasis via Peroxisome Proliferator-Activated Receptor- $\alpha$  in an In Vitro Model of Alzheimer's Disease*. BIOMEDICINES 2022 May 26;10(6):1236. Article. IF(2021)=4.757; citations=4. **co-first authors**.
4. **Valenza M**, Scuderi C. *How useful are biomarkers for the diagnosis of Alzheimer's disease and especially for its therapy?* NEURAL REGENERATION RESEARCH 2022 Oct;17(10):2205-2207. Article. IF(2021)=6.058, citations=5
5. **Valenza M**, Steardo L Jr, Steardo L, Verkhatsky A & Scuderi C. *Systemic Inflammation and Astrocyte Reactivity in the Neuropsychiatric Sequelae of COVID-19: Focus on Autism Spectrum Disorders*. FRONTIERS in CELLULAR NEUROSCIENCE 2021. 15, 748136. Article. IF(2021)=6.147; citations=6
6. Friuli M, Eramo B, **Valenza M**, Scuderi C., Provensi G, Romano A. *Targeting the oxytocinergic system: a possible pharmacological strategy for the treatment of inflammation occurring in different chronic diseases*. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 2021, 22(19), 10250. Article. IF(2021)=6.208; citations=9. **Contribution:** general revision of the literature and writing the first draft regarding the contribute of glia to specific inflammatory conditions and the actions of oxytocin on glial cells.
7. **Valenza M**, Facchinetti R, Menegoni G, Steardo L, Scuderi C. *Alternative targets to fight Alzheimer's disease: Focus on astrocytes*. BIOMOLECULES 2021. Apr 19;11(4):600. Review. IF(2021)=6.064; citations=14
8. Facchinetti R <sup>1</sup>, **Valenza M** <sup>1</sup>, Bronzuoli MR, Ratano P, Steardo L, Campolongo P and Scuderi C. *Looking for a treatment for the early stage of Alzheimer's disease: Preclinical evidence with co-ultramicronized palmitoylethanolamide and luteolin*. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 2020. May 27;21(11):E3802. Article. IF(2020)=5.924; citations=16. **co-first authors**.

9. **Valenza M**, Blasio A, DiLeo A, Cottone P, Sabino V. *Sigma receptor-induced heavy drinking in rats: Modulation by the opioid receptor system*. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR 2020. May;192:172914. Article. [IF\(2020\)=3.533; citations=5](#).
10. **Valenza M \***, Windisch KA, Butelman RE, Reed B, Kreek MJ Effects of *Kappa opioid receptor blockade by LY2540240, a selective short-acting antagonist, during chronic extended-access cocaine self-administration and re-exposure in rat*. PSYCHOPHARMACOLOGY 2020. Apr;237(4):1147-1160. Article. [IF\(2020\)=4.530; citations=10](#). **\*corresponding author**.
11. **Valenza M \***, Facchinetti R, Steardo L and Scuderi C. *Altered waste disposal system in aging and Alzheimer's disease: focus on astrocytic aquaporin-4*. FRONTIERS in PHARMACOLOGY 2020. ecollection 2019. Jan 29;10:1656. Article. [IF\(2020\)=5.811; citations=42](#). **\*corresponding author**.
12. Bronzuoli MR, Facchinetti R, **Valenza M**, Cassano T, Steardo L and Scuderi C. *Astrocyte function is affected by aging and not Alzheimer's disease: a preliminary investigation in hippocampi of 3xTg-AD mice*. FRONTIERS in PHARMACOLOGY 2019 Jun 6;10:644. Article. [IF\(2019\)= 4.225; citations=24](#). **Contribution:** interpretation of data. First draft writing and contribution to the final version of the manuscript. Contribution to the responses to the reviewers.
13. **Valenza M \***, Butelman R E, Kreek MJ. *Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats*. PSYCHOPHARMACOLOGY 2017. 234: 2219. Article. [IF\(2017\)=3.222; citations=36](#). **\*corresponding author**.
14. **Valenza M \***, Picetti R, Yuferov V, Butelman R E, Kreek MJ. *Strain and cocaine-induced differential opioid gene expression may predispose Lewis but not Fischer rats to escalate cocaine self-administration*. NEUROPHARMACOLOGY 2016. Jun;105:639-50. Article. [IF\(2016\)=5.012; citations=22](#). **\*corresponding author**.
15. **Valenza M**, DiLeo A, Steardo L, Cottone P, Sabino V. *Ethanol-related behaviors in mice lacking the sigma-1 receptor*. BEHAVIOURAL BRAIN RESEARCH 2016. Jan 15;297:196-203. Article. [IF\(2016\)=3.002; citations=12](#)
16. Smith KL, Rao R, Velázquez-Sánchez C, **Valenza M**, Giuliano C, Everitt B, Sabino V, Cottone P. *The uncompetitive N-methyl-D- aspartate antagonist memantine reduces binge-like eating, food-seeking behavior and compulsive eating: role of the nucleus accumbens shell*. NEUROPSYCHOPHARMACOLOGY 2015. Mar 13;40(5):1163-71. Article. [IF\(2015\)=6.399; citations=47](#). **Contribution:** executor of surgeries with placement of brain cannulas, in situ administration of memantine and binge-eating behavioral tests. Responsible and executor of the compulsive eating behavior experiment with data preparation and statistical analysis. – *Press release from Boston University*
17. **Valenza M**, Steardo L, Sabino V, Cottone P. *Diet-Induced Obesity and Diet-Resistant rats: differences in the rewarding and anorectic effects of D-Amphetamine*. PSYCHOPHARMACOLOGY (Berl). 2015 Sep;232(17):3215-26. Article. [IF\(2015\)=3.540; citations=24](#).
18. Blasio A, **Valenza M**, Iyer M R, Rice K C, Steardo L, Hayashi T, Cottone P, Sabino, V. *Sigma-1 Receptor Mediates Acquisition of Alcohol Drinking and Seeking behavior in Alcohol-Preferring Rats*. BEHAVIOURAL BRAIN RESEARCH 2015. 6 Jul 1;287:315-22. Article. [IF\(2015\)=3.002; citations=26](#). **Contribution:** responsible for and executor of experiments on self-administration of alcohol in different cohorts of rats with or without drug administration. Contributed to data curation, statistical analysis and first draft writing.



19. Dore R, **Valenza M**, Wang X, Rice KC, Sabino V, Cottone P. *The inverse agonist of CB1 receptor SRI141716A blocks compulsive eating and risk-taking behavior*. ADDICTION BIOLOGY 2014. Sep;19(5):849-61. Article. IF(2014)=5.359; citations=44. **Contribution:** responsible for and executor of behavioral experiments on food intake with and without rimonabant treatment. Data analysis and first draft writing.
20. Baiamonte BA, **Valenza M**, Roltsch EA, Whitaker AM, Baynes BB, Sabino V, Gilpin NW. *Nicotine Dependence Produces Hyperalgesia that is Mediated by Corticotropin-Releasing Factor-1 Receptors (CRF1Rs) in Central Amygdala (CeA)*. NEUROPHARMACOLOGY 2014. Feb;77:217-23. Article. IF(2014)=5.106; citations=40. **Contribution:** responsible for and executor of molecular biology experiments on amygdala samples by quantitative PCR. Statistical analysis of data.
21. Scuderi C, Stecca C, **Valenza M**, Ratano P, Bronzuoli MR, Bartoli S, Steardo L, Pompili E, Fumagalli L, Campolongo P, Steardo L. *Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease*. CELL DEATH & DISEASE 2014. Sep 11;5:e1419. Article. IF(2014)=5.014; citations=74. **Contribution:** Executor of surgeries, drug treatment, behavioral experiments and molecular biological analyzes. Contribution to first draft writing and to response to reviewers.
22. Cottone P, Wang X, Park JW, **Valenza M**, Blasio A, Kwak J, Iyer MR, Steardo L, Rice KC, Hayashi T, Sabino V. *Antagonism of sigma-1 receptors blocks compulsive-like eating*. NEUROPSYCHOPHARMACOLOGY 2012. Nov;37(12):2593-604. Article. IF(2012)=8.678; citations=72. **Contribution:** responsible for and executor of binge-eating behavioral experiments in a cohort of rats with or without drug treatment with final brain area sampling. Data curation and statistical analysis. Contribution to responding to reviewers. – *Selected as Hot paper from the National Institute of Drug of abuse*.
23. Iemolo A<sup>1</sup>, **Valenza M**<sup>1</sup>, Tozier L, Knapp CM, Kornetsky C, Steardo L, Sabino V, Cottone P. *Withdrawal from chronic, intermittent access to a highly palatable food induces depressive-like behavior in compulsive eating rats*. BEHAVIOURAL PHARMACOLOGY 2012. Sep;23(5-6):593-602. Article. IF(2012)=2.301; citations=68. <sup>1</sup>**co-first authors**.
24. Scuderi C, **Valenza M**, Stecca C, Esposito G, Carratù MR, Steardo L. *Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglia cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-alpha*. JOURNAL OF NEUROINFLAMMATION 2012. Mar 9;9:49. Article. IF(2012)=4.351; citations=104. **Contribution:** Executor of in vitro experiments, primary cell culture set-up and processing, setting-up protocol for organotypic cultures and processing. Executor of molecular biology experiments.
25. Esposito G, Scuderi C, **Valenza M**<sup>2</sup>, Togna GI, Latina V, De Filippis D, Cipriano M, Carratù MR, Iuvone T, Steardo L. *Cannabidiol reduces  $\beta$ -induced neuroinflammation and promotes hippocampal neurogenesis through PPAR $\gamma$  involvement*. PLoS One 2011. 6(12):e28668. Article. IF(2011)=4.092; citations=276. <sup>2</sup>**second author**. **Contribution:** executor of in vitro experiments and of molecular biology experiments.
26. Scuderi C, Esposito G, Blasio A, **Valenza M**, Arietti P, Steardo L Jr, Carnuccio R, De Filippis D, Petrosino S, Iuvone T, Di Marzo V, Steardo L. *Palmitoylethanolamide counteracts reactive astrogliosis induced by beta-amyloid peptide*. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 2011. Dec;15(12):2664-74. Article. IF(2011)=4.125; citations=90. **Contribution:** executor of in vitro experiments, primary cell culture set-up and processing, and of molecular biology experiments.

## Part XII-B – List of editorial and conference meeting abstracts published in peer-reviewed journals

*Impact Factor of the year of publication from Journal Citation Report - JCR (Web of Science); Citations from Web of Science.*

1. Walwyn WM, **Valenza M** \*. *Kappa opioid receptors revealed: disentangling the pharmacology to open up new therapeutic strategies*. FRONTIERS in PHARMACOLOGY – Section Translational Pharmacology 2022. Aug 12;13:973780 Editorial. IF(2021)=5.988; citations=0 \***last & corresponding author**.
2. Scuderi C, Facchinetti R, Steardo L, **Valenza M**. *Neuroinflammation in Alzheimer's disease: friend or foe?* FASEB JOURNAL 2020. Apr, suppl.1. Conference meeting abstract; IF(2020)=5.191, citations=8.
3. **Valenza M**, Butelman R E, Kreek MJ. *Chronic Extended Access (18-H) Intravenous Cocaine Self-Administration Procedure: Pattern of Cocaine Intake and Role of the Kappa Opioid Receptor*. NEUROPSYCHOPHARMACOLOGY 2016. (41) S1 Pages: S439-S440. Conference meeting abstract; IF(2016)=6.403, citations=0.
4. **Valenza M**, Butelman R E, Kreek MJ. *The Novel Short-Acting Kappa Opioid Receptor Antagonist LY2444296 Blocks Neuroendocrine and Behavioral Effects of Chronic but not Acute Mild Stress in Rats*. NEUROPSYCHOPHARMACOLOGY 2015. (40) S1 Pages: S173-S174. Conference meeting abstract; IF(2015)=6.399, citations=0.
5. **Valenza M**, Picetti R, Yuferov V, Kreek MJ. *Predisposing genetic differences contribute to vulnerability to escalate cocaine intake in rats*. DRUG AND ALCOHOL DEPENDENCE 2015. 146 Page e9. Conference meeting abstract; IF(2015)=3.466, citations=0.
6. Cottone P, Smith KL, Rao RR, **Valenza M**, Velazquez-Sanchez C, Sabino V. *NMDA Receptors in the Nucleus Accumbens Shell Mediate Compulsive Eating of Palatable Food*. NEUROPSYCHOPHARMACOLOGY 2013. (38) S2. Pages: S582-S582. Conference meeting abstract; IF(2013)=7.833, citations=0.
7. Scuderi C, **Valenza M**, Esposito G, Steardo, L. *Palmitoylethanolamide attenuates astrocyte activation and neuroinflammation in an animal model of Alzheimer's disease*. SHOCK 2011. Volume 36 Page 31-31. Conference meeting abstract; IF(2011)=2.848, citations=0.

## XII-C – Organization of international and national symposia and congresses

1. The 9<sup>th</sup> Conference of the Mediterranean Neuroscience Society (MNS) 2023. Symposium proposed and approved (to be held on Oct 2023): From neuronal plasticity to glia protection: mapping the path of *resilience and vulnerability to stress*. **Organizer and Chair**: Dr. Marta Valenza. Co-chair: Prof. Carla Nasca, New York University (NY) US;
2. European College of Neuropsychopharmacology (ECNP) 2024. Symposium proposed (under evaluation): Allostatic load in Mood and Cognitive Disorders: Novel Mechanisms of Brain Plasticity for Personalized Interventions. **Organizer and Chair**: Dr. Marta Valenza;
3. “International Meet on Neurology and Brain Disorders (NEUROMEET2024)”, to be held in May 2024 in Prague, Czech Republic. **Scientific Committee Member** for the organization of the international congress;
4. Workshop on Glial Cells-Neurons Crosstalk in CNS health and disease, University of Turin, Virtual edition, Oct. 3, 2020. **Invited Chairperson** for the session of invited oral communications.

## XII-D – Invited lectures and seminars

1. Università di Bari “Aldo Moro”. Dip di Farmacia-Scienze del Farmaco. Bari, Apr. 12, 2023  
Title of the seminar “*Le tecniche per lo studio dei farmaci: studi in vivo comportamentali e di funzione*”
2. The Rockefeller University, Apr. 5, 2013. New York (NY) US.  
Lecture title: *Diet-Induced Obesity and Diet Resistant rats: differences in the rewarding and anorectic effects of D-Amphetamine.*

## XII-E – Invited speaker at international and national conferences

1. The 9<sup>th</sup> Conference of the Mediterranean Neuroscience Society (MNS) 2023. Carthage, Tunisia Oct,2023  
Invited at the symposium *Non-neuronal cells as guardians of CNS homeostasis: relevance in brain development and diseases*. Speech Title: *Role of astrocytes in mediating oligodendrocyte maturation and function: evidence with co-ultramicrosized palmitoylethanolamide/luteolin in models of beta-amyloid toxicity.*  
**Valenza M**, Facchinetti R, Gomiero C, Ciarla C, Campolongo P, Steardo L and Scuderi C.
2. Italian Society of Neuroscience Annual Meeting (SINS). Virtual, Sept 10, 2021  
Invited at the symposium “*The inflamed brain in neurological diseases: moving from hypothesis to treatment*”. Speech Title *Unravelling the complex role of neuroinflammation in Alzheimer’s disease: preclinical evidence using palmitoylethanolamide.*  
**Valenza M**, Facchinetti R, Scuderi C.
3. The 55<sup>th</sup> American College of NeuroPsychopharmacology (ACNP) Annual Meeting. Hollywood (FL) US. Dec. 04 - 08, 2016. *Chronic Extended Access (18-H) Intravenous Cocaine Self-Administration procedure: Analysis of Pattern of Cocaine Intake and Role of the Kappa Opioid Receptor*. **Valenza M**, Butelman ER, Kreek MJ. Abstract published in NEUROPSYCHOPHARMACOLOGY 2016. (41) S1 Pages: S439-S440.
4. The Kappa Therapeutics Conference. Apr 5, 2015. Chapel Hill (NC) US  
*Basal and cocaine-induced differential opioid gene expression may predispose Lewis but not Fischer rats to escalate cocaine consumption.*  
**Valenza M**, Butelman ER, Kreek MJ.
5. The 54<sup>th</sup> American College of NeuroPsychopharmacology (ACNP) Annual Meeting. Hollywood (FL) US. Dec. 06 - 10, 2015. *The novel short-acting kappa opioid receptor antagonist LY244496 blocks neuroendocrine and behavioral effects of chronic but not acute mild stress in rats.*  
**Valenza M**, Butelman ER, Kreek MJ. Abstract published in NEUROPSYCHOPHARMACOLOGY 2015. (40) S1 Pages: S173-S174.

## XII-F – Speaker at international congresses

1. The 19<sup>th</sup> World Congress of basic and clinical pharmacology (WCP). Glasgow, Scotland, July 2023  
*Resilient and vulnerable rats to acute foot shock stress show different glial cell responses: possible rescue of pathological alterations by a single ketamine administration*. Selected for oral communication.  
**Valenza M**, Facchinetti R, Milanese, Musazzi, Bonanno G, Steardo L, Bonifacino T and Scuderi C.

2. The 8<sup>th</sup> European Congress of Pharmacology (EPHAR) 2021. Virtual, Dec 8, 2021.  
*Targeting neuroinflammation with a combination of palmitoylethanolamide and luteolin in an animal model of prodromal Alzheimer's disease*. Oral communication.  
**Valenza M**, Facchinetti R, Steardo L, Scuderi C.
3. The III edition of More Than Neurons: changing the paradigm for therapeutic avenues. Turin (ITA) Dec 16, 2022. *Looking at the glial cell contributes to acute stress resilience and vulnerability in rats*.  
**Valenza M**, Facchinetti R, Musazzi L, Barbon A, Milanese M, Popoli M, Bonanno GB, Steardo L, Bonifacino T and Scuderi C.
4. The 46<sup>th</sup> Society for Neuroscience (SfN) annual meeting 2016, San Diego (CA) US  
*The novel short-acting kappa opioid receptor antagonist LY244496 blocks neuroendocrine and behavioral effects of chronic, but not acute stress in rats*.  
**Valenza M**, Butelman ER, Kreek MJ.
5. The 44<sup>th</sup> Society for Neuroscience (SfN) annual meeting 2014. Washington (DC) US  
*Predisposing genetic differences in opioid peptides and receptors mRNA levels contribute to the escalation of cocaine intake*. **Valenza M**, Picetti R., Yuferov V, Kreek MJ
6. The College on Problems of Drug Dependence (CPDD) Annual meeting 2014. San Juan (PR) US  
*Predisposing genetic differences contribute to the vulnerability to escalate cocaine intake in rats*.  
**Valenza M**, Picetti R, Yuferov V, Kreek MJ. Abstract published in DRUG AND ALCOHOL DEPENDENCE 2015. 146 Page e9.
7. The 43<sup>rd</sup> Society for Neuroscience (SfN) annual meeting 2013. San Diego (CA) US  
*Ethanol drinking behavior in TRI Sardinian alcohol-preferring rats is modulated by a cross-talk between the sigma-1 and the opioid receptors systems*.  
**Valenza M**, Blasio A, Cottone P, Sabino V
8. The 42<sup>nd</sup> Society for Neuroscience (SfN) annual meeting 2012. New Orleans (LU) US  
*Diet Induced Obesity and Diet Resistant rats: differences in the rewarding and anorectic effect of D-Amphetamine*. **Valenza M**, Sabino V, Steardo L, Cottone P

## XII-H – Speaker at national conferences

1. The 41<sup>st</sup> Congresso Nazionale della Società Italiana di Farmacologia (SIF). Roma, Nov 19, 2022.  
*Stress resilience and vulnerability: do glial cells play a role?* Oral communication.  
**Valenza M**, Facchinetti R, Musazzi L, Barbon A, Milanese M, Popoli M, Bonanno G, Steardo L, Bonifacino T and Scuderi C.
2. XIV Seminario Nazionale per Dottorandi in Farmacologia e Scienze affini (SIF). Siena, Certosa di Pontignano, 20-23 Sept, 2010. Oral communication.  
*Palmitoylethanolamide exerts anti-inflammatory and neuroprotective effects through PPAR $\alpha$  involvement in models of beta-amyloid toxicity*.  
**Valenza M**, Scuderi C, Esposito G, Steardo L.
3. The 5<sup>th</sup> Brainstorming Research Assembly for Young Neuroscientists, Rome, Sept 29, 2022  
*Co-ultramicrosized Palmitoylethanolamide/Luteolin prevents alteration in astrocyte-oligodendrocyte crosstalk relevant for myelination in an in vitro model of  $\beta$ -amyloid toxicity*.  
**Valenza M**, Facchinetti R, Scuderi C.
4. Workshop on Glial Cells-Neurons Crosstalk in CNS health and disease, 2020. Virtual due to pandemic. *Do glial cells have a role in binge-eating disorder?*  
**Valenza M**, Micioni di Bonaventura MV, Facchinetti R, Menegoni G, Cifani C, Scuderi C.

5. 38° Congresso Nazionale della Società Italiana di Farmacologia, 2017. Rimini, Oct. 25 -28, 2017  
*Effect of a novel selective short-acting Kappa Opioid Receptor Antagonist on cocaine intake during escalation and upon re-exposure after withdrawal.*  
**Valenza M**, Butelman ER, Kreek MJ
6. Workshop della Società Italiana di Farmacologia “Cannabinoids: from biology to clinic”. Cagliari, 2011. *Cannabidiol controls  $\beta$ -induced neuroinflammation and promotes hippocampal neurogenesis through PPAR $\gamma$  involvement.* **Valenza M**, Scuderi C, Esposito G, Steardo L

## **XII-I – Co-author in conference meeting abstracts for international and national conferences**

1. The 19<sup>th</sup> World Congress of Basic & Clinical Pharmacology 2023. Glasgow July, 2023.  
*Co-ultramicrosized palmitoylethanolamide/luteolin restores the astrocyte-oligodendrocyte cross-talk via peroxisome proliferator-activated receptor- $\alpha$  in an in vitro model of Alzheimer’s disease.*  
Abstract authors: Facchinetti R, **Valenza M**, Gomiero C, Steardo L, Campolongo P, Scuderi C. Selected for oral communication.
2. The 9<sup>th</sup> Conference of the Mediterranean Neuroscience Society (MNS) 2023. Carthage, Tunisia Oct,2023. *Molecular changes of glia and neurons in the maladaptive response to acute stress are prevented by a single administration of ketamine in a rodent model of PTSD.* Abstract authors: Facchinetti R, **Valenza M**, Ciarla C, Bonifacino T, Milanese M, Musazzi L, Scuderi C.
3. The III edition of More Than Neurons: changing the paradigm for therapeutic avenues. Turin 15-17 Dec, 2022.  *$\beta$ -amyloid impairs the astrocyte-oligodendrocyte crosstalk required for myelination: preclinical evidence with co-ultramicrosized palmitoylethanolamide/luteolin.* Abstract authors: Facchinetti R, **Valenza M**, Voci V, Ciarla C, Gomiero C, Steardo L, Campolongo P, Scuderi C.
4. The 5<sup>th</sup> Brainstorming Research Assembly for Young Neuroscientists, Rome, Sept. 2022  
*The role of glial cells in the adaptive and maladaptive response to acute stress: evidence from a preclinical model.* Abstract authors: Facchinetti R, **Valenza M**, Bonifacino T, Milanese M, Musazzi L, Steardo L, Scuderi C.
5. The Experimental Biology Meeting 2020, San Diego, CA (USA)  
*Neuroinflammation in Alzheimer’s disease: friend or foe?*  
Abstract authors: Scuderi C, Facchinetti R, Steardo L, **Valenza M**. published in the FASEB JOURNAL 2020. Apr, suppl.1
6. International congress of the Mediterranean Society of Neurosciences (MNS) 2019, Marrakech, Marocco “*Involvement of glial cells in the resilient or vulnerable response to acute stress: evidence from a preclinical model*”. Abstract authors: Facchinetti R, Bronzuoli MR, **Valenza M**, Rebosio C, Bonanno G, Steardo L, Scuderi C.
7. The American College of NeuroPsychopharmacology (ACNP) annual meeting, 2013. Hollywood, FL  
*NMDA Receptors in the Nucleus Accumbens Shell Mediate Compulsive Eating of Palatable Food*  
Abstract authors: Cottone P, Smith KL, Rao RR, **Valenza M**, Giuliano C, Everitt B, Sabino V.– invited contribute. published in 2013. (38) S2. Pages: S582-S582.
8. The 43<sup>rd</sup> Society for Neuroscience (SfN) annual meeting 2013. San Diego, CA.  
*The inverse agonist of CB1 receptor SR141716 blocks compulsive eating of palatable food.*  
Abstract authors: Cottone P, Dore R, **Valenza M**, Sabino V.
9. The 43<sup>rd</sup> Society for Neuroscience (SfN) annual meeting 2013. San Diego, CA. *The uncompetitive NMDA receptor antagonist memantine blocks compulsive eating of palatable food.* Abstract authors: Smith KL, Rao RR, **Valenza M**, Sabino V, Cottone P.

10. The XIV European Shock Society International Congress, 2011. Taormina, Italy  
*Palmitoylethanolamide attenuates astrocyte activation and neuroinflammation in an animal model of Alzheimer's disease.* Abstract authors: Scuderi C, **Valenza M**, Esposito G, Steardo L. published in SHOCK 2011. Volume 36 Page 31-31.
11. The 41<sup>st</sup> Society for Neuroscience (SfN) annual meeting, 2010. San Diego, CA.  
*Palmitoylethanolamide blunts beta amyloid-induced reactive astrogliosis.* Abstract authors: Scuderi C, Esposito G, Blasio A, **Valenza M**, Steardo L.
12. WorldPharma2010. Copenhagen, NL *Cannabidiol inhibits beta amyloid-induced reactive gliosis through peroxisome proliferator-activated receptor-gamma involvement.* Abstract authors: Esposito G, Scuderi C, De Filippis D, **Valenza M**, Iuvone T, Steardo L.
13. WorldPharma 2010. Copenhagen, NL.  
*Antiinflammatory/neuroprotective properties of palmitoylethanolamide in a model of beta-amyloid neurotoxicity.* Abstract authors: Scuderi C, Esposito G, Blasio A, **Valenza M**, Steardo L.
14. The 40<sup>th</sup> Society for Neuroscience (SfN) annual meeting, 2009. Chicago, IL.  
*Cannabidiol inhibits beta amyloid-induced reactive gliosis through peroxisome proliferator-activated receptor-gamma involvement.* Abstract authors: Scuderi C, Blasio A, **Valenza M**, Steardo L, Esposito G.
15. XXV Conference of young Italian Society of Pharmacology (SIF) Pharmacologists 2023.  
*Ketamine controls glial reactivity and neuronal changes observed in a new rodent model of resilience/vulnerability to acute stress.* Abstract authors: Facchinetti R, **Valenza M**, Ciarla C, Bonifacino T, Milanese M, Musazzi L, Scuderi C.
16. Annual Meeting of the Italian Society of Neuroscience (SINS). Turin, 2023  
*Ketamine controls glial reactivity and neuronal changes observed in the prefrontal cortex of rats vulnerable to acute footshock stress.* Abstract authors: Facchinetti R, **Valenza M**, Ciarla C, Bonifacino T, Milanese M, Musazzi L, Scuderi C.
17. Italian society of Pharmacology (SIF) national congress, Rome, Nov 15-18, 2022.  
 *$\beta$ -amyloid impairs the astrocyte-oligodendrocyte crosstalk required for myelination: preclinical evidence with co-ultramicrosized Palmitoylethanolamide/Luteolin.* Abstract authors: Facchinetti R, **Valenza M**, Gomiero C, Steardo L, Campolongo P, Scuderi C. - Selected oral communication.
18. Convegno "Contributo dei Centri per i Disturbi Cognitivi e le Demenze nella gestione integrata dei pazienti". Istituto Superiore di Sanità, Rome, Nov 17-18, 2022. La spettroscopia di risonanza magnetica in vivo in un modello murino di Alzheimer:effetti della palmitoiletanolamide. Abstract authors: Canese R, Palombelli G, Bukke VN, **Valenza M**, Scuderi C, Cassano T. Selected oral communication
19. Italian society of Pharmacology (SIF) national congress. Virtual edition, 2021.  
*"Investigating on the effects of ketamine on neurons and glial cells after an acute stress: evidence from a preclinical model".* Abstract authors: Facchinetti R, **Valenza M**, Menegoni G, Bonifacino T, Milanese M, Bonanno G, Popoli M, Steardo L, Musazzi L, Scuderi C. - Selected oral communication
20. Congress "Glial cells-neuron crosstalk in CNS health and disease". Virtual Oct 1-3, 2020  
*Exploring the effects of ketamine on glial cells after an acute stress: evidence from a preclinical model.* Abstract authors: Facchinetti R. **Valenza M**, Menegoni G, Bonifacino T, Milanese M, Bonanno G, Popoli M, Steardo L, Musazzi L, Scuderi C.

21. National Congress of PhD students of Neuroscience. Naples (IT), 2019  
*Preventing neuroinflammation with co-ultramicrosized palmitoylethanolamide/luteolin in an animal model of prodromal Alzheimer's disease*.  
Abstract authors: Facchinetti R, Bronzuoli MR, **Valenza M**, Scuderi C.
22. National congress of the Italian Society of Pharmacology (SIF). Florence (IT) 2019  
*"Involvement of glial cells in the resilient or vulnerable response to acute stress: evidence from a preclinical model"*. Abstract authors: Facchinetti R, Bronzuoli MR, **Valenza M**, Rebosio C, Bonanno G, Steardo L, Scuderi C
23. XVI National Seminar for PhD students in Pharmacology and Related Science 2012. Rimini, Italy.  
*Palmitoylethanolamide counteracts reactive astrogliosis in in vitro models of Alzheimer's disease*.  
Abstract authors: Stecca C, Scuderi C, **Valenza M**, Esposito G, Steardo L.
24. The Italian Society of Pharmacology Workshop "Cannabinoids: present to future". Ferrara, Italy, 2012.  
*Palmitoylethanolamide counteracts reactive astrogliosis in in vitro models of Alzheimer's*.  
Abstract authors: Stecca C, Scuderi C, **Valenza M**, Esposito G, Steardo L.
25. The Italian Society of Pharmacology Workshop "Cannabinoids: present to future". Ferrara, Italy, 2012.  
*Cannabinoids and PPARs: new tools for Alzheimer's disease treatment*.  
Abstract authors: Scuderi C, **Valenza M**, Steardo L.
26. The Italian Society of Pharmacology Workshop "Cannabinoids: from biology to clinic". Cagliari, Italy, 2011. *Palmitoylethanolamide counteracts reactive gliosis in an in vivo model of Alzheimer's disease*. Abstract authors: Scuderi C, **Valenza M**, Ratano P, Stecca C, Campolongo P, Steardo L.
27. The 35<sup>th</sup> annual meeting of the Italian Society of Pharmacology. Bologna, Italy, 2011.  
*Palmitoylethanolamide is able to attenuate astrocyte activation and neuroinflammation in an in vivo model of Alzheimer's disease*. Abstract authors: Scuderi C, **Valenza M**, Stecca C, Ratano P, Campolongo P, Steardo L.
28. The Italian Society of Pharmacology Workshop "The Emotional Brain: from neurobiology to new therapeutic opportunities". September 2011, Rome, Italy. *Palmitoylethanolamide is able to attenuate astrocyte activation and neuroinflammation in models of Alzheimer's disease*". Abstract authors: Scuderi C, **Valenza M**, Stecca C, Campolongo P Steardo L.
29. The 34<sup>th</sup> annual meeting of the Italian Society of Pharmacology, 2009. Rimini, Italy.  
*PPARgamma mediates cannabidiol antiinflammatory and neuroprotective effects in an in vitro model of Alzheimer's disease*. Abstract authors: Scuderi C, Blasio A, **Valenza M**, Esposito G, Steardo L.

### Part XIII – Editorial activities

Year	Journal	IF	Role
2021 – present	Current Alzheimer Research (Bentham) – Section: “Neuroinflammation in Alzheimer's Disease”	3.5	<b>Editorial Board member - Section Editor</b>
2021 – present	Frontiers in Pharmacology – section: Translational Pharmacology	5.8	<b>Editorial Board member</b> Editor for 4 articles
2021 – present	International Journal of Molecular Sciences	5.9	<b>Invited Reviewer Board member</b>
01/2023 – present	Biomolecules	6.06	<b>Guest Editor</b> for a Special Issue entitled "From Biomarkers to Therapy to Puzzle Out Alzheimer's Disease"
12/2022 - present	Current Alzheimer Research	3.5	<b>Guest Editor</b> for a collection entitled “ <i>Glia-glia and glia-neurons crosstalk in dementia</i> ”
2021 – 2022	Frontiers in Pharmacology – section: Translational Pharmacology	5.8	<b>Guest Associate Editor</b> of a research topic entitled “ <i>Kappa opioid receptors revealed: disentangling the pharmacology to open up new therapeutic strategies</i> ”
2022 – present	Frontiers in Public Health – section: Substance Use Disorders and Behavioral Addictions	6.5	<b>Invited Review Editor</b>
2020 – present	Frontiers in Neuroscience – section: Neuropharmacology	4.7	<b>Invited Review Editor</b>
2020 – present	Frontiers in Pharmacology – section: Neuropharmacology	5.8	<b>Invited Review Editor</b>
2020 – present	Frontiers in Pharmacology – section: Experimental Pharmacology and Drug Discovery	5.8	<b>Invited Review Editor</b>
2016 – present	Neuropharmacology (Elsevier)	5.3	<b>Ad hoc Reviewer</b>
	Neuropeptides (Elsevier)	3.3	
	Biocybernetics and Biomedical Engineering (Elsevier)	4.3	
	Neuropsychiatric Disease and Treatment (Dove)	2.6	
	J of Neuroinflammation (Springer Nature)	8.3	
	Brain Sciences (MDPI)	3.4	
	Cannabis and Cannabinoid Research (Liebert)	4.8	
	Frontiers in Psychiatry	5.4	
Addiction Biology (Wiley)	4.1		



## Part XIV – Third mission activities

Year	Institution	Activity
2022-2023	Third mission educational-teaching project titled Adolescenti e "cervelli diversi": differenze di genere nella vulnerabilità agli effetti delle sostanze d'abuso organized by the Dept. of Physiology and Pharmacology "V. Erspamer" and funded by Sapienza University of Rome (Prof.ssa P. Campolongo)	<b>Invited lectures</b> (4 hours) + <b>"hands-on laboratory"</b> (2 hours) for children (13-14 years old).
2021	National Institute of Drug of Abuse (NIDA) notes are short papers describing selected original articles in layman terms and published on the NIDA website for divulgative purposes	<b>Scientific consultant</b> for a NIDA note published on April 5, 2021: <a href="https://www.drugabuse.gov/news-events/nida-notes/2021/04/targeting-kappa-opioid-receptor-reduce-drug-use-relapse">https://www.drugabuse.gov/news-events/nida-notes/2021/04/targeting-kappa-opioid-receptor-reduce-drug-use-relapse</a>
2020	Neurosciencenews.com	<b>Media outreach</b> "Reducing early brain inflammation could slow Alzheimer's progression" <a href="https://neurosciencenews.com/alzheimers-brain-inflammation-16251/">https://neurosciencenews.com/alzheimers-brain-inflammation-16251/</a>
Dec 20, 2019	The Parish Church Santa Maria delle Grazie al Trionfale. Rome, Italy	<b>Invited lecture</b> (1.5 hours) on "The science of pleasure" as part of an educational program for children (11-17 years old)
2017	Videomaker company "Te lo spiego" (animated video disseminating scientific content)	<b>Scientific consultant</b> for a video on "Marijuana" posted on the major social networks to explain Marijuana effects in human body in layman terms. <a href="https://youtube.com/watch?v=kSgvhB23060">youtube.com/watch?v=kSgvhB23060</a>
2015 - 2017	RockEdu Science Outreach at The Rockefeller University, New York, NY	<b>Participant to outreach activities</b> as scientist volunteer. <b>Scientist crew member</b> at the 2 <sup>nd</sup> and 4 <sup>th</sup> science outreach event Science Saturday: one full day scientific event (May 2, 2015 and May 8, 2017) with scientific talks, demonstrations, and interactive experiments open to children, their parents and teachers. <b>Organizer of a scientific booth</b> at the 3 <sup>rd</sup> annual Science Saturday on May 7, 2016. Organized the interactive station titled "Brain & Behavior" with activities/experiments for children (6 - 14 years old) and an educational scientific poster.

La sottoscritta è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del Codice penale e delle leggi speciali. Inoltre, la sottoscritta autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 675/96 del 31 dicembre 1996

Signature \_\_\_\_\_